Recombinant Human FGFR3, Fc-tagged

• Cat.No.: FGFR3-28836TH
• Product Overview: Human Recombinant FGFR3 Fc Chimera fused with Xa cleavage site with the Fc part of human IgG1 produced in baculovirus and expressed in insect cells, 190 kDa.

Specification

• Description: This gene encodes a member of the fibroblast growth factor receptor (FGFR) family, with its amino acid sequence being highly conserved between members and among divergent species. FGFR family members differ from one another in their ligand affinities and tissue distribution. A full-length representative protein would consist of an extracellular region, composed of three immunoglobulin-like domains, a single hydrophobic membrane-spanning segment and a cytoplasmic tyrosine kinase domain. The extracellular portion of the protein interacts with fibroblast growth factors, setting in motion a cascade of downstream signals, ultimately influencing mitogenesis and differentiation. This particular family member binds acidic and basic fibroblast growth hormone and plays a role in bone development and maintenance. Mutations in this gene lead to craniosynostosis and multiple types of skeletal dysplasia. Three alternatively spliced transcript variants that encode different protein isoforms have been described.
• Conjugation: Fc
• Tissue specificity: Expressed in brain, kidney and testis. Very low or no expression in spleen, heart, and muscle. In 20- to 22-week old fetuses it is expressed at high level in kidney, lung, small intestine and brain, and to a lower degree in spleen, liver, and muscle. Isof
• Biological activity: Biological Activity:Determined by its ability to inhibit human FGF acidic-dependent proliferation on R1 cells. The ED50 for this effect is typically at 15.0-30.0 ng/ml.
• Form: Lyophilised:Reconstitute in sterile PBS not less than 100 μg/ml, which can then be further diluted to other aqueous solutions.
• Purity: >90% by SDS-PAGE
• Storage buffer: Preservative: None
• Storage: Store at -20°C or lower.Aliquot to avoid repeated freezing and thawing.
• Sequence Similarities: Belongs to the protein kinase superfamily. Tyr protein kinase family. Fibroblast growth factor receptor subfamily.Contains 3 Ig-like C2-type (immunoglobulin-like) domains.Contains 1 protein kinase domain.

Gene Information

• Gene Name: FGFR3 fibroblast growth factor receptor 3 [ Homo sapiens ]
• Official Symbol: FGFR3
• Synonyms: FGFR3; fibroblast growth factor receptor 3; ACH, achondroplasia, thanatophoric dwarfism; CD333; CEK2; JTK4
• Gene ID: 2261
• mRNA Refseq: NM_000142
• Protein Refseq: NP_000133
• MIM: 134934
• Uniprot ID: P22607
• Chromosome Location: 4p16.3
• Pathway: Bladder cancer, organism-specific biosystem; Bladder cancer, conserved biosystem; Downstream signaling of activated FGFR, organism-specific biosystem; Endochondral Ossification, organism-specific biosystem; Endocytosis, organism-specific biosystem
• Function: ATP binding; fibroblast growth factor binding; fibroblast growth factor binding; fibroblast growth factor-activated receptor activity; nucleotide binding

Reviews

01/13/2020

Researchers who have utilized FGFR3 protein praise its exceptional performance and reliability in their experiments.

03/26/2018

Its high sensitivity enables the identification of low abundance targets, making it highly valuable in immunological research.

08/29/2017

Its stability and compatibility with electron microscopy techniques make it an ideal candidate for studying protein structures at high resolution.

Q&As

How does FGFR3 testing assist in personalized medicine approaches?

FGFR3 testing helps identify specific genetic mutations, allowing for personalized treatment plans tailored to an individual's genetic profile.

Is FGFR3 testing routinely conducted in cancer diagnosis?

FGFR3 testing is becoming more common, especially in cases where specific cancers associated with FGFR3 mutations are suspected.

Can FGFR3 be a prognostic marker in cancer?

Yes, FGFR3 status can serve as a prognostic marker, influencing the prediction of disease progression and patient outcomes.

Are there targeted therapies based on FGFR3 in cancer treatment?

Yes, FGFR3-targeted therapies are being developed for cancer treatment, particularly for patients with FGFR3 mutations.

How is FGFR3 targeted in cancer therapy?

FGFR3-targeted therapies may involve small molecule inhibitors or monoclonal antibodies that specifically block the activity of mutated FGFR3.